P2Y12 Platelet Inhibitor class drugs

3 results

  • brilinta

    (Ticagrelor)
    AstraZeneca Pharmaceuticals LP
    BRILINTA is indicated for reducing the risk of cardiovascular death, myocardial infarction, and stroke in patients with acute coronary syndrome or a history of myocardial infarction, as well as for those with high-risk coronary artery disease. It also decreases stroke risk in patients with acute ischemic stroke or transient ischemic attack.
    Medication Details
    Drug Interactions

  • kengreal

    (cangrelor)
    Chiesi USA, Inc.
    KENGREAL is indicated as an adjunct to percutaneous coronary intervention (PCI) to lower the risk of periprocedural myocardial infarction, repeat coronary revascularization, and stent thrombosis in patients who have not received a P2Y12 platelet inhibitor and are not on a glycoprotein IIb/IIIa inhibitor.
    Medication Details
    Drug Interactions

  • ticagrelor

    (ticagrelor)
    Solco Healthcare U.S., LLC
    Ticagrelor is indicated for reducing the risk of cardiovascular death, myocardial infarction, and stroke in patients with acute coronary syndrome or a history of myocardial infarction. It also lowers the risk of stent thrombosis and is used to reduce stroke risk in acute ischemic stroke and high-risk transient ischemic attack patients.
    Medication Details
    Drug Interactions